The efficacy of osimertinib can be evaluated by a significant increase in the PFS (median: 18.9 vs. 10.2 months) and overall survival (median: 38.6 vs. 31.8 months) of patients with advanced EGFR-positive or T790M-positive NSCLC patients (18). This evidence concerns the gene EGFR and non-small cell lung carcinoma.